271 related articles for article (PubMed ID: 30400287)
1. Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety.
Gu X; He D; Li C; Wang H; Yang G
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400287
[TBL] [Abstract][Full Text] [Related]
2. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.
Sakemura R; Terakura S; Watanabe K; Julamanee J; Takagi E; Miyao K; Koyama D; Goto T; Hanajiri R; Nishida T; Murata M; Kiyoi H
Cancer Immunol Res; 2016 Aug; 4(8):658-68. PubMed ID: 27329987
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
Ambrose C; Su L; Wu L; Dufort FJ; Sanford T; Birt A; Hackel BJ; Hombach A; Abken H; Lobb RR; Rennert PD
PLoS One; 2021; 16(3):e0247701. PubMed ID: 33735268
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Nonviral
Lin Z; Liu X; Liu T; Gao H; Wang S; Zhu X; Rong L; Cheng J; Cai Z; Xu F; Tan X; Lv L; Li Z; Sun Y; Qian Q
Front Immunol; 2021; 12():802705. PubMed ID: 35082789
[TBL] [Abstract][Full Text] [Related]
5. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
Fousek K; Watanabe J; Joseph SK; George A; An X; Byrd TT; Morris JS; Luong A; Martínez-Paniagua MA; Sanber K; Navai SA; Gad AZ; Salsman VS; Mathew PR; Kim HN; Wagner DL; Brunetti L; Jang A; Baker ML; Varadarajan N; Hegde M; Kim YM; Heisterkamp N; Abdel-Azim H; Ahmed N
Leukemia; 2021 Jan; 35(1):75-89. PubMed ID: 32205861
[TBL] [Abstract][Full Text] [Related]
6. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
[TBL] [Abstract][Full Text] [Related]
7. CAR T-Cell Therapy: Progress and Prospects.
Wilkins O; Keeler AM; Flotte TR
Hum Gene Ther Methods; 2017 Apr; 28(2):61-66. PubMed ID: 28330372
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
9. Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
Yang M; Wang L; Ni M; Neuber B; Wang S; Gong W; Sauer T; Schubert ML; Hückelhoven-Krauss A; Xia R; Ge J; Kleist C; Eckstein V; Sellner L; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
Front Immunol; 2021; 12():670088. PubMed ID: 34122428
[TBL] [Abstract][Full Text] [Related]
10. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.
Drent E; Poels R; Mulders MJ; van de Donk NWCJ; Themeli M; Lokhorst HM; Mutis T
PLoS One; 2018; 13(5):e0197349. PubMed ID: 29847570
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.
Rivière I; Sadelain M
Mol Ther; 2017 May; 25(5):1117-1124. PubMed ID: 28456379
[TBL] [Abstract][Full Text] [Related]
13. Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production.
Dingfelder J; Aigner M; Taubmann J; Minopoulou I; Park S; Kaplan CD; Cheng JK; Van Blarcom T; Schett G; Mackensen A; Lutzny-Geier G
Transplant Cell Ther; 2024 Jun; 30(6):582.e1-582.e10. PubMed ID: 38548226
[TBL] [Abstract][Full Text] [Related]
14. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
Julamanee J; Terakura S; Umemura K; Adachi Y; Miyao K; Okuno S; Takagi E; Sakai T; Koyama D; Goto T; Hanajiri R; Hudecek M; Steinberger P; Leitner J; Nishida T; Murata M; Kiyoi H
Mol Ther; 2021 Sep; 29(9):2677-2690. PubMed ID: 33940156
[TBL] [Abstract][Full Text] [Related]
15. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
[TBL] [Abstract][Full Text] [Related]
16. Modulation of chimeric antigen receptor surface expression by a small molecule switch.
Juillerat A; Tkach D; Busser BW; Temburni S; Valton J; Duclert A; Poirot L; Depil S; Duchateau P
BMC Biotechnol; 2019 Jul; 19(1):44. PubMed ID: 31269942
[TBL] [Abstract][Full Text] [Related]
17. Basic Procedures for Detection and Cytotoxicity of Chimeric Antigen Receptors.
Mihara K; Yoshida T; Bhattacharyya J
Methods Mol Biol; 2019; 1904():299-306. PubMed ID: 30539476
[TBL] [Abstract][Full Text] [Related]
18. AAVS1 site-specific integration of the CAR gene into human primary T cells using a linear closed-ended AAV-based DNA vector.
Chen W; Tan L; Zhou Q; Li W; Li T; Zhang C; Wu J
J Gene Med; 2020 Apr; 22(4):e3157. PubMed ID: 31901177
[TBL] [Abstract][Full Text] [Related]
19. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
[TBL] [Abstract][Full Text] [Related]
20. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
